An Obesity Drugmaker's Critical Coming Weeks
In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's Qsymia could impact the stock in the coming weeks.
Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market, and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.
The article An Obesity Drugmaker's Critical Coming Weeks originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.